Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy. Academic Article uri icon

Overview

abstract

  • Radioiodinated metaiodobenzylguanidine [(131)I-MIBG] is commonly used to treat resistant neuroblastoma or metastatic pheochromocytoma [MP] with little non-hematopoietic toxicity. We describe here transient sialoadenitis, a previously unreported complication. Ten patients [9 neuroblastoma and 1 MP] received 12-18 mCi/kg of (131)I-MIBG. Five patients had bilateral parotid swelling, two with associated buccal discomfort within 24 hr of injection which subsided within 48 hr. Grade 3 or 4 serum amylase elevation was documented in 8/8 patients tested [median 1,336; range: 576-8,830 U/L] which normalized [25-125 U/L] within 4-14 [median 5.5] days. Serum lipase remained normal. Patients did not develop subsequent dry mouth or dysphagia.

publication date

  • June 1, 2008

Research

keywords

  • 3-Iodobenzylguanidine
  • Antineoplastic Agents
  • Radiopharmaceuticals
  • Sialadenitis

Identity

Scopus Document Identifier

  • 42349094437

Digital Object Identifier (DOI)

  • 10.1002/pbc.21391

PubMed ID

  • 17973318

Additional Document Info

volume

  • 50

issue

  • 6